恩格列净与盐皮质激素受体拮抗剂在射血分数降低心衰中的相互作用:EMPEROR-Reduced 研究
该研究为 EMPEROR-Reduced 试验的二次分析,比较恩格列净与安慰剂在 3,730 例射血分数降低心衰患者中的效果,其中 71% 基线使用盐皮质激素受体拮抗剂(MRA)。结果显示,无论是否使用 MRA,恩格列净对主要终点、多数疗效终点和安全性的影响相似(交互作用 P > 0.20)。恩格列净组 MRA 停药率更低,且严重高钾血症更少见。
要点
- 无论是否使用 MRA,恩格列净对心衰和肾脏结局的获益一致。
- 恩格列净可减少 MRA 的停药,并降低严重高钾血症风险。
- MRA 使用状态未显著改变恩格列净的疗效或安全性。
核心结论
- 在 EMPEROR-Reduced 中,MRA 的使用不影响恩格列净减少心衰不良结局和肾脏结局的效果。
- 恩格列净治疗与 MRA 停药减少相关。
研究设计与样本
- EMPEROR-Reduced 试验的二次分析,比较恩格列净与安慰剂在 3,730 例射血分数降低心衰患者中的效果。
- 71% 的患者在随机化时使用 MRA。
主要发现
- 恩格列净对主要终点、多数疗效终点和安全性的影响在是否使用 MRA 的患者中相似(交互作用 P > 0.20)。
- 心血管死亡的风险比:MRA 使用者为 0.82(95%CI 0.65–1.05),非使用者为 1.19(95%CI 0.82–1.71),交互作用 P = 0.10。
- 全因死亡呈现相似模式(交互作用 P = 0.098)。
- 基线未使用 MRA 的患者中,恩格列净组随机化后启动 MRA 治疗的可能性比安慰剂组低 35%(HR 0.65;95%CI 0.49–0.85)。
- 基线使用 MRA 的患者中,恩格列净组随机化后停用 MRA 的可能性比安慰剂组低 22%(HR 0.78;95%CI 0.64–0.96)。
临床怎么用
- 对于射血分数降低心衰患者,无论是否使用 MRA,均可考虑恩格列净以降低心衰和肾脏不良结局。
- 恩格列净可能有助于维持 MRA 治疗并减少严重高钾血症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 inhibitors favorably influence the clinical course of patients with heart failure and reduced ejection fraction. OBJECTIVES: This study sought to study the mutual influence of empagliflozin and MRAs in EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction). METHODS: Secondary analysis that compared the effects of empagliflozin versus placebo in 3,730 patients with heart failure and a reduced ejection fraction, of whom 71% used MRAs at randomization. RESULTS: The effects of empagliflozin on the primary endpoint, on most efficacy endpoints, and on safety were similar in patients receiving or not receiving an MRA (interaction p > 0.20). For cardiovascular death, the hazard ratios for the effect of empagliflozin versus placebo were 0.82 (95% confidence interval [CI]: 0.65 to 1.05) in MRA users and 1.19 (95% CI: 0.82 to 1.71) in MRA nonusers (interaction p = 0.10); a similar pattern was seen for all-cause mortality (interaction p = 0.098). Among MRA nonusers at baseline, patients in the empagliflozin group were 35% less likely than those in the placebo group to initiate treatment with an MRA following randomization (hazard ratio: 0.65; 95% CI: 0.49 to 0.85). Among MRA users at baseline, patients in the empagliflozin group were 22% less likely than those in the placebo group to discontinue treatment with an MRA following randomization (hazard ratio: 0.78; 95% CI: 0.64 to 0.96). Severe hyperkalemia was less common in the empagliflozin group. CONCLUSIONS: In EMPEROR-Reduced, the use of MRAs did not influence the effect of empagliflozin to reduce adverse heart failure and renal outcomes. Treatment with empagliflozin was associated with less discontinuation of MRAs. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977).
引用
- Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021. PMID: 33736821. doi:10.1016/j.jacc.2021.01.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。